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for the MRIdian plans. The mean results and the standard 
deviations are summarized in the table. 
 
 
 
Conclusion: A comparable PTV dose coverage between the 3 
plans was found for rectal cancer, with a HI advantage for 
the PTV1 for the MRIdian plan. Differences were described 
for OaRs, especially for low dose areas (V5 Body). MRIdian 
allowed to reach dosimetrical goals comparable to RapidArc 
and IMRT gold standards. The evaluation of a possible 
reduction in PTV margin and a proper target coverage by MRI 
based gating will be analyzed when the system will become 
operative at Gemelli ART.  
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Purpose or Objective: The cervix-uterus shows large day-to-
day variation in position and size, mainly depending on 
bladder and rectum filling. Image-guided adaptive 
radiotherapy with a library of plans (LOP) is a strategy to 
mitigate these large variations, resulting in less dose to 
organs at risk (OAR) compared to the use of a single plan with 
a population-based PTV margin. A further reduction of OAR 
dose can be achieved using proton therapy. However, it is 
challenging to achieve a target coverage that is robust for 
range and position uncertainties. The aim of this study is to 
compare target coverage of robustly optimized photon and 
proton therapy plans using a LOP adaptive strategy for 
cervical cancer. 
 
Material and Methods: Five cervical cancer patients treated 
with photon therapy were retrospectively included. For each 
patient a full and empty bladder planning CT and weekly 
repeat CTs were acquired. Depending on the magnitude of 
cervix-uterus motion, one to three ITV sub ranges were 
generated by interpolation of the CTV delineations on full 
and empty bladder CT. Target and OARs were delineated on 
all repeat CTs. Robustly optimized photon (VMAT) library 
plans and proton (IMPT) library plans were generated with a 
prescribed dose of 46 Gy in 23 fractions to the ITV. For robust 
optimization, a position uncertainty of 0.8 cm was applied; 
for protons 3% range uncertainty was included as well. The 
plans were required to have sufficient target coverage 
(V95%>99%) for both the nominal scenario and twelve 
scenarios with different range and position errors. Both for 
protons and photons the actual delivered dose was simulated. 
Repeat CTs were registered to the full bladder planning CT 
using bony anatomy, the best fitting library plan was selected 
and the dose was recalculated. The DVH for the whole 
treatment was estimated by adding and scaling DVHs. The 
target coverage was evaluated for the total CTV as well as 
the CTVs of the corpus uteri, cervix, vagina and elective 
lymph nodes. 
 
Results: For the total CTV, on average, the V95% for the 
whole treatment was 99.9% (range 97.3%-99.8%) for photons 
and 96.3% (93.5%-98.1%) for protons. The V95% of the corpus 
uteri was 95.7% (86.3%-99.9%) and 88.7% (68.4%-99.9%) for 
photons and protons, respectively. Figure 1 shows a repeat 
CT with insufficient target coverage both for photons and 
protons. The elective lymph nodes received sufficient dose 
with photons, on average, V95% was 99.1% (98.1%-99.8%). 
With protons this volume decreased to 96.2%(94.9%-98.8%). 
For the cervix and vagina no differences between the use of 
photons and protons were observed. 
 
 
 
Conclusion: The robustly optimized proton therapy plans did 
not result in an adequate target coverage for all patients for 
the realistic robustness parameters used. For some cases the 
used LOP strategy is not sufficient to cope with the large 
movements of the cervix-uterus for both modalities. The 
impact of underdosing is larger using protons than using 
photons. 
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Purpose or Objective: Dose calculation is currently based on 
the density map provided by CT. However, for delineation of 
the prostate gland and organs at risk T2-weighted MR imaging 
is the gold standard. Dose calculation based on MR 
information would remove the need for a CT scan and avoid 
the uncertainty related to registration of the images. Pseudo-
CT generation from MR scans has recently become available. 
This study investigates the validity of dose calculation based 
on pseudo CT created with commercial software (MR for 
Calculating ATtenuation – MRCAT) compared to standard CT 
based dose calculation. 
 
Material and Methods: Seven high risk prostate cancer 
patients were MR and CT scanned. The clinical, curatively 
intended treatment (78 Gy in 39 Fx) using single arc VMAT 
was based on the conventional CT. From the MR scan pseudo-
CT were created using MRCAT (Philips, Helsinki, Finland). To 
eliminate dose comparison uncertainties related to patient 
positioning differences between CT and MR rigid CT-MR 
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registration was performed. The VMAT plan was transferred 
to the pseudo-CT and dose calculation was performed using 
Pinnacle (V9.10). Pass rate of the Gamma index was used to 
evaluate the similarity of the dose distributions. The dose 
acceptance criterion was evaluated as a percentage of the 
prescribed dose applying 2 %/2 mm and 1 %/1mm criteria. 
 
Results: MRCAT was generated for six of the seven patients. 
One patients’ pelvic anatomy was not correctly recognized by 
the software model, which prohibited MRCAT reconstruction. 
Pass rates for both acceptance criteria are summarized in 
table 1. For 2%/2 mm, pass rates are high, above 97.6% for 
all analyzed structures. Even for the 1%/1 mm criterion, pass 
rates are generally above 97%. In patient 3, lower pass rates 
in PTV78, seminal vesicles and rectum are observed. For this 
patient the gamma values above one are located mainly in 
and around an air cavity in the rectum (see figure 1). MRCAT 
does not assign air density to air cavities inside the patient, 
leading to the observed dose differences. However, in the 
pelvic region it might be at least as good an approximation to 
treat air cavities as water due to the mobility of the rectal 
air during the treatment course. As seen in figure 1, gamma 
values above one are also present close to the surface of the 
patient, which is caused by differences in definition of the 
outer contour of the patient. 
 
 
 
Conclusion: Overall the pseudo-CT based dose calculations 
are very similar to the CT based calculation for prostate 
cancer patients. The MRCAT software classifies internal air 
cavities as water density leading to dose differences 
compared directly to CT. In terms of the dose precision 
observed in this study the MRCAT is able to substitute the 
standard CT simulation, but a larger cohort of patients is 
needed to validate this finding. This will also reveal whether 
bone recognition capability is sufficiently versatile for 
standard clinical use. 
 
 
 
 
 
 
OC-0083  
When using gating in left tangential breast irradiation? A 
planning decision tool 
N. Dinapoli
1Università Cattolica del Sacro Cuore -Policlinico A. Gemelli, 
Radiation Oncology Department, Rome, Italy 
1, D. Piro1, M. Bianchi1, S. Teodoli2, G.C. 
Mattiucci1, L. Azario2, A. Martino1, F. Marazzi1, G. Mantini1, 
V. Valentini1 
2Università Cattolica del Sacro Cuore -Policlinico A. Gemelli, 
Physics Institute, Rome, Italy 
 
Purpose or Objective: The use of gating in tangential breast 
irradiation has shown to reduce the dose delivered to the 
heart, resulting in the possibility of decreasing heart toxicity 
in long time surviving patients. The use of gating requires to 
identify which patients could be addressed to this methodic 
by comparing planning results of gated and not-gated 
simulation CT based plans. However, the required double CT 
scan (with and without gating technology), for patients 
undergoing to left-breast tangential radiation treatment, can 
result in working overhead for RTTs executing CTs and for 
planners that have to produce two opponent plans for 
allowing final gated, or not-gated treatment decision. In this 
work a tool for deciding which patients could be selected for 
gating procedures by using only not gated CT scan is 
presented. 
 
Material and Methods: Patients addressed to left-breast 
tangential irradiation without need to irradiate supra-
clavicular nodes have been retrospectively recruited in this 
study. Both gated and not-gated simulation CT were available 
for all of them. Two series of opponent, gated and not-gated, 
treatment plans have been produced and analyzed using 
Varian™ Eclipse workstation. DVHs have been extracted from 
plans and have been analyzed in order to detect which 
dosimetrical parameters are able to predict the final 
outcome: mean heart dose in gated treatment plan. 
Maximum heart distance (MHD) has been also recorded. A 
multiple linear regression model has been used to predict the 
final outcome. 
 
Results: 100 patients have been enrolled in this study and 
200 plans on 100 gated-CT and 100 not-gated CT have been 
produced. 10 patients showed mean not-gated CT heart dose 
(MNGHD) > 5 Gy (institutional threshold for addressing the 
patient to gating), resulting in a 90% overhead in terms of 
performed gated-CTs and plans. The final model shows the 
possibility to predict mean heart dose in gated treatment 
plan with a p-value < 2.2e-16, adjusted R-squared = 0.5486, 
using not gated CT based planning and geometrical 
parameters summarized as follows: 
 
Coefficients name:  β value  P-val - Pr(>|t|) 
Intercept  0.92151  2.27e-11 
V31.5 Gy Lung Basal  -4.20188  0.000299 
Mean Basal CT Heart Dose   0.54065  1.29e-13 
Basal MHD  -0.44137  0.000748 
 
In order to easily predict which gated-CT mean heart dose 
would result if patients underwent to this scanning procedure 
a nomogram has been produced allowing the users to 
manually calculate this value without scanning the patients 
with gated CT (figure 1).  
 
 
